Real-world implementation, deployment and validation of early detection tools and lifestyle enhancement


Around 7 million people are living with Alzheimer’s disease in Europe alone, and that number is set to double by 2050. Although there is no cure, there are now treatments that can slow the progress of the disease. In addition, we now have a greater understanding of the lifestyle changes that can reduce people’s risk of Alzheimer’s disease. We also know that the first signs of Alzheimer’s disease appear in the brain several years before start to develop symptoms. This effectively means that there is a huge window of opportunity for people to take action to delay disease onset, and slow disease progression.

The aim of the AD-RIDDLE project is to revolutionise the way Alzheimer’s disease is detected, diagnosed, prevented, and treated. It will do this by delivering a ‘toolbox platform’ of validated resources with resources designed for patients, caregivers and healthcare providers. This toolbox platform is designed to be modular and customizable, allowing health systems and healthcare providers to tailor component tools to the unique needs of different settings and practices.

The toolbox platform will offer a digital community engagement portal comprising self-guided assessment tools for people concerned about their dementia risk, as well as pathways for referral to the appropriate healthcare services and resources that ordinary people can easily use.

The platform will also include an array of screening and diagnostic tools to help identify those at risk of developing Alzheimer’s disease and diagnose those who already have it. These tools will include both blood-based biomarker tests and digital cognitive assessments. Healthcare providers will also have access to a decision support toolkit, powered by algorithms, to assist in the diagnosis, prevention and management of Alzheimer’s disease. Finally, the platform will help to ensure that patients benefit from personalised therapies including lifestyle interventions and medicines.

The modular toolbox will be tested in different healthcare settings (e.g. memory clinics, primary care) across six European countries. Data from AD-RIDDLE will be hosted by the European Platform for Neurodegenerative Diseases (EPND), an Innovative Medicines Initiative project developing secure, accessible and sustainable ways to share research data and biosamples.

AD-RIDDLE brings together patient organisations, representatives of diverse industries, universities, healthcare providers and regulatory bodies. Together, they will help to pioneer a new approach to the way we prevent, diagnose and manage Alzheimer’s disease, and empower patients with practical information to help them safeguard their own cognitive health for as long as possible.

Achievements & News


  Show participants on map
Universities, research organisations, public bodies, non-profit groups
  • Alzheimer'S Disease International The International Federation Of Alzheimer'S Disease And Related Disorders Societies Inc, Lincolnshire, Illinois, United States
  • Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain
  • Goeteborgs Universitet, Gothenburg, Sweden
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Itä-Suomen yliopisto, Kuopio, Finland
  • Karolinska Institutet, Stockholm, Sweden
  • Lunds Universitet, Lund, Sweden
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • Region Stockholm, Stockholm, Sweden
  • Stichting Amsterdam Umc, Amsterdam, Netherlands
  • Stiftelsen Fingers Brain Health Institute, Stockholm, Sweden
  • Universita Degli Studi Di Perugia, Perugia, Italy
  • Universiteit Maastricht, Maastricht, Netherlands
  • University Of Leicester, Leicester, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Alzheimer Europe, Luxembourg, Luxembourg
  • Synapse Research Management Partners SL, Barcelona, Spain
IHI industry partners
  • Fujirebio Europe Nv, Zwijnaarde Gent, Belgium
  • Gates Ventures Llc, Kirkland, United States
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Contributing partners
  • C2n Diagnostics Llc, St. Louis, United States
  • Cambridge Cognition Limited, Cambridge, United Kingdom
  • Combinostics Oy, Valkeakoski, Finland
  • Davos Alzheimer'S Collaborative, Geneva, Switzerland
  • Neotiv GMBH, Magdeburg, Germany

NameEU funding in €
Alzheimer Europe538 000
Alzheimer'S Disease International The International Federation Of Alzheimer'S Disease And Related Disorders Societies Inc157 000
Fundacio Barcelonabeta Brain Research Center1 038 000
Goeteborgs Universitet1 095 250
Itä-Suomen yliopisto929 000
Karolinska Institutet734 250
Lunds Universitet1 095 250
Region Stockholm2 932 750
Stichting Amsterdam Umc1 121 250
Stiftelsen Fingers Brain Health Institute590 250
Synapse Research Management Partners SL803 250
Universita Degli Studi Di Perugia519 000
Universiteit Maastricht537 000
Total Cost12 090 250